Drawing for PALVATA

USPTO serial 85262092

PALVATA

Reviewed by CopyMark Law Group

Reg. 4647300Status 710
Filing date
Status date
Registration date
Dec 2, 2014
Examiner
EULIN, INGRID C
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with PALVATA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Robert J. Gorman

1400 N. Goodman StreetLaw DepartmentRochester, NY 14609

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and products for use in dermatology; antifungal preparations; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the treatment of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations and substances for use in chemotherapy; Pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for the treatment of fungal infections, onychomycosis, tinea infections, and similar diseases of the skin and nails; pharmaceutical preparations and substances for use in dermatological conditionsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 18, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 18, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 18, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 18, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 18, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 18, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 18, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 18, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 11, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Feb 11, 2026ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Apr 16, 2025ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Jul 9, 2021C8..CANCELLED SEC. 8 (6-YR)—
Dec 2, 2019REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 10, 2019ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Mar 20, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Oct 16, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 16, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 21, 2018ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jan 11, 2017ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Mar 3, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 21, 2015ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Dec 2, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 16, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 27, 2014NPUBNOTICE OF PUBLICATION—
Aug 8, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 4, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 20, 2014CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 19, 2014CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jan 30, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 29, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 29, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 22, 2014ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 22, 2014REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 31, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 31, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 31, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 11, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 11, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 11, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 16, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 16, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 16, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 7, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 7, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 7, 2013ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Aug 1, 2012ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Jul 6, 2012GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jul 6, 2012GNSIINQUIRY TO SUSPENSION E-MAILED—
Jul 6, 2012CNSISUSPENSION INQUIRY WRITTEN—
Jul 3, 2012RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jun 27, 2012TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 27, 2012ALIEASSIGNED TO LIE—
Jun 26, 2012CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 26, 2012ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Dec 15, 2011GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 15, 2011GNSLLETTER OF SUSPENSION E-MAILED—
Dec 15, 2011CNSLSUSPENSION LETTER WRITTEN—
Dec 15, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 15, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 15, 2011ALIEASSIGNED TO LIE—
Dec 9, 2011TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 9, 2011GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2011GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2011CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2011DOCKASSIGNED TO EXAMINER—
Apr 6, 2011ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Mar 14, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 12, 2011NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance